FRINK Linked Data Fragments server

Matches in Wikidata for { <http://www.wikidata.org/entity/Q38988059> ?p ?o ?g. }

• Q38988059 description "2017 nî lūn-bûn" @default.
• Q38988059 description "2017年の論文" @default.
• Q38988059 description "2017年学术文章" @default.
• Q38988059 description "2017年学术文章" @default.
• Q38988059 description "2017年学术文章" @default.
• Q38988059 description "2017年学术文章" @default.
• Q38988059 description "2017年学术文章" @default.
• Q38988059 description "2017年學術文章" @default.
• Q38988059 description "2017年學術文章" @default.
• Q38988059 description "2017年學術文章" @default.
• Q38988059 description "2017年學術文章" @default.
• Q38988059 description "2017年學術文章" @default.
• Q38988059 description "2017年學術文章" @default.
• Q38988059 description "2017년 논문" @default.
• Q38988059 description "article científic" @default.
• Q38988059 description "article scientific" @default.
• Q38988059 description "article scientifique (publié 2017)" @default.
• Q38988059 description "articol științific" @default.
• Q38988059 description "articolo scientifico" @default.
• Q38988059 description "artigo científico (publicado na 2017)" @default.
• Q38988059 description "artigo científico (publicado na 2017)" @default.
• Q38988059 description "artigo científico" @default.
• Q38988059 description "artikull shkencor" @default.
• Q38988059 description "artikulong pang-agham" @default.
• Q38988059 description "artykuł naukowy" @default.
• Q38988059 description "artículo científico publicado en 2017" @default.
• Q38988059 description "artículu científicu espublizáu en 2017" @default.
• Q38988059 description "bilimsel makale" @default.
• Q38988059 description "bài báo khoa học" @default.
• Q38988059 description "mokslinis straipsnis" @default.
• Q38988059 description "naučni članak" @default.
• Q38988059 description "scienca artikolo" @default.
• Q38988059 description "scientific article" @default.
• Q38988059 description "teaduslik artikkel" @default.
• Q38988059 description "tieteellinen artikkeli" @default.
• Q38988059 description "tudományos cikk" @default.
• Q38988059 description "vedecký článok" @default.
• Q38988059 description "vetenskaplig artikel" @default.
• Q38988059 description "videnskabelig artikel (udgivet 2017)" @default.
• Q38988059 description "vitenskapelig artikkel" @default.
• Q38988059 description "vitskapeleg artikkel" @default.
• Q38988059 description "vědecký článek" @default.
• Q38988059 description "wetenschappelijk artikel" @default.
• Q38988059 description "wissenschaftlicher Artikel" @default.
• Q38988059 description "επιστημονικό άρθρο" @default.
• Q38988059 description "мақолаи илмӣ" @default.
• Q38988059 description "мақолаи илмӣ" @default.
• Q38988059 description "наукова стаття, опублікована в січні 2017" @default.
• Q38988059 description "научна статия" @default.
• Q38988059 description "научная статья" @default.
• Q38988059 description "научни чланак" @default.
• Q38988059 description "научни чланак" @default.
• Q38988059 description "գիտական հոդված" @default.
• Q38988059 description "מאמר מדעי" @default.
• Q38988059 description "سائنسی مضمون" @default.
• Q38988059 description "مقالة علمية" @default.
• Q38988059 description "مقالهٔ علمی" @default.
• Q38988059 description "২০১৭-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ" @default.
• Q38988059 description "บทความทางวิทยาศาสตร์" @default.
• Q38988059 description "სამეცნიერო სტატია" @default.
• Q38988059 name "Following the results of the EMPA-REG OUTCOME trial with empagliflozin, is it possible to speak of a class effect?" @default.
• Q38988059 name "Following the results of the EMPA-REG OUTCOME trial with empagliflozin, is it possible to speak of a class effect?" @default.
• Q38988059 name "Following the results of the EMPA-REG OUTCOME trial with empagliflozin, is it possible to speak of a class effect?" @default.
• Q38988059 type Item @default.
• Q38988059 label "Following the results of the EMPA-REG OUTCOME trial with empagliflozin, is it possible to speak of a class effect?" @default.
• Q38988059 label "Following the results of the EMPA-REG OUTCOME trial with empagliflozin, is it possible to speak of a class effect?" @default.
• Q38988059 label "Following the results of the EMPA-REG OUTCOME trial with empagliflozin, is it possible to speak of a class effect?" @default.
• Q38988059 prefLabel "Following the results of the EMPA-REG OUTCOME trial with empagliflozin, is it possible to speak of a class effect?" @default.
• Q38988059 prefLabel "Following the results of the EMPA-REG OUTCOME trial with empagliflozin, is it possible to speak of a class effect?" @default.
• Q38988059 prefLabel "Following the results of the EMPA-REG OUTCOME trial with empagliflozin, is it possible to speak of a class effect?" @default.
• Q38988059 P1433 Q38988059-D75ACA05-748F-4539-9C94-0E3FD721953B @default.
• Q38988059 P1476 Q38988059-99E79922-3681-4434-A023-26FC28DEA977 @default.
• Q38988059 P2093 Q38988059-0F43C73D-A0C2-4FA7-81A5-EB89E0FC5F1B @default.
• Q38988059 P2093 Q38988059-0FA9BFCF-92A0-432A-A9B3-D9C67639B385 @default.
• Q38988059 P2093 Q38988059-70AAEADB-71EB-4671-8F2C-8D570643FCE2 @default.
• Q38988059 P275 Q38988059-5d03a959-a125-4137-b0c8-c915e1484bc6 @default.
• Q38988059 P2860 Q38988059-208B6470-F9B6-42B8-A1AB-3A5E920AD81E @default.
• Q38988059 P2860 Q38988059-22787A77-331C-4A7D-9277-F943A8AA8574 @default.
• Q38988059 P2860 Q38988059-6DC4011A-1669-49DD-B865-C4B9DA8541B6 @default.
• Q38988059 P2860 Q38988059-6F36509F-7AA0-4E15-B5C8-15601A81F844 @default.
• Q38988059 P2860 Q38988059-710E27F6-C403-4C5F-A3E3-623550D22F79 @default.
• Q38988059 P2860 Q38988059-736E9461-0C59-43D7-A6F1-94DD6851B11B @default.
• Q38988059 P2860 Q38988059-8DDD645B-100C-4FF7-8B3A-95C801D88DF4 @default.
• Q38988059 P2860 Q38988059-B269C616-BEC5-48F9-897E-7A51B267F105 @default.
• Q38988059 P2860 Q38988059-B9CD6AB4-49BE-45CB-AEA6-773C34E55DA3 @default.
• Q38988059 P2860 Q38988059-D53B0DF0-390D-43FE-B36A-CA33CFD5B022 @default.
• Q38988059 P304 Q38988059-71D09E32-CA19-4BCE-8C6C-32FD9103EBE1 @default.
• Q38988059 P31 Q38988059-29FC9558-7F17-408A-956B-324E1A3CDD5D @default.
• Q38988059 P356 Q38988059-9A320C7F-C425-481E-813B-0FAF976CD741 @default.
• Q38988059 P407 Q38988059-8DE9B374-2471-49AC-BA01-6A9354740947 @default.
• Q38988059 P478 Q38988059-427A9E21-0318-4FA0-BC49-2DE4938C217F @default.
• Q38988059 P50 Q38988059-647948CE-CFB6-47F6-B2DD-7D315D26CABB @default.
• Q38988059 P577 Q38988059-B7974F4B-7C53-44A0-9AA2-31176493953D @default.
• Q38988059 P6216 Q38988059-d1556672-d6f8-4cfc-ba85-6627353f3592 @default.
• Q38988059 P698 Q38988059-87FD6BDD-EDD4-455B-AD7A-1CC6970F6407 @default.
• Q38988059 P932 Q38988059-35797FAB-3FF1-4041-B1A6-AB04E98ED0D8 @default.
• Q38988059 P356 IJGM.S115566 @default.
• Q38988059 P698 28144158 @default.
• Q38988059 P1433 Q6051402 @default.
• Q38988059 P1476 "Following the results of the EMPA-REG OUTCOME trial with empagliflozin, is it possible to speak of a class effect?" @default.

• next